Ensysce Biosciences, Inc. (ENSC)

Market Cap	4.57M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
Shares Out	1.41M
EPS (ttm)	-11.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,114
Open	3.150
Previous Close	3.120
Day's Range	3.050 - 3.580
52-Week Range	2.115 - 14.670
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 10, 2025

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: ENSC
• Website: https://www.ensysce.com

Financial Performance

In 2024, Ensysce Biosciences's revenue was $5.21 million, an increase of 133.58% compared to the previous year's $2.23 million. Losses were -$7.99 million, -24.83% less than in 2023.